VYGR
HEALTHCAREVoyager Therapeutics Inc
$4.17+0.27 (+6.92%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VYGR Today?
No stock-specific AI insight has been generated for VYGR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.65$5.55
$4.17
Fundamentals
Market Cap$252M
P/E Ratio—
EPS$-2.04
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-3.0%
Debt / Equity—
Trading
Volume834K
Avg Volume (10D)—
Shares Outstanding60.4M
VYGR News
20 articles- Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Voyager Reports First Quarter 2026 Financial and Operating ResultsYahoo Finance·May 7, 2026
- Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s DiseaseYahoo Finance·Apr 27, 2026
- Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic DebutMarketbeat·Mar 23, 2026
- Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?Yahoo Finance·Mar 12, 2026
- Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Mar 9, 2026
- Voyager Therapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 9, 2026
- Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsYahoo Finance·Mar 9, 2026
- Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028Marketbeat·Mar 2, 2026
- Fortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Lag EstimatesYahoo Finance·Feb 26, 2026
- Voyager to Present at Upcoming Investor ConferencesYahoo Finance·Feb 9, 2026
- Gene Therapy Market Outlook 2026-2031, Featuring Profiles of REGENXBIO, Oxford Biomedica, Voyager Therapeutics and MoreYahoo Finance·Jan 23, 2026
- Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish CoverageYahoo Finance·Dec 10, 2025
- We're A Little Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn RateYahoo Finance·Nov 24, 2025
- Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance·Nov 10, 2025
- Voyager Therapeutics: Q3 Earnings SnapshotYahoo Finance·Nov 10, 2025
- Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal DementiaYahoo Finance·Nov 10, 2025
- Voyager Reports Third Quarter 2025 Financial and Operating ResultsYahoo Finance·Nov 10, 2025
- Moderna (MRNA) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance·Nov 6, 2025
- Owning 44% shares,institutional owners seem interested in Voyager Therapeutics, Inc. (NASDAQ:VYGR),Yahoo Finance·Oct 28, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$3.90
Day High$0.00
Day Low$0.00
52 Week High$5.55
52 Week Low$2.65
52-Week Range
$2.65$5.55
$4.17
Fundamentals
Market Cap$252M
P/E Ratio—
EPS$-2.04
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-3.0%
Debt / Equity—
Trading
Volume834K
Avg Volume (10D)—
Shares Outstanding60.4M
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—